Abstract
Introduction: Deep infiltrating endometriosis is a common cause of pelvic pain.
However, some patients have limited problems that may be controlled by medical treatment, so avoiding the potentially severe complications of major surgery. This approach requires detailed knowledge on quality of life and clinical symptoms over time. The aim of the study was to monitor these parameters in patients with rectosigmoid endometriosis treated with oral contraceptives, oral gestagens, and/or the levonorgestrel‐releasing intrauterine device. Moreover, nodule size measurements performed with transvaginal sonography were correlated to severity of symptoms.
Material and methods: Conservatively treated patients on oral contraceptives, oral gestagens, or the levonorgestrel-releasing intrauterine device underwent transvaginal sonography and answered a self‐administered questionnaire regarding clinical symptoms and quality of life (Short Form 36 and Endometriosis Health Profile 30) at baseline, and 6 and 12 months later.
Results: Eighty women completed the follow up. Scores of quality of life were comparable
to normative data for Danish women of similar age and did not change with
time. No association between change in size of the rectosigmoid nodule and change in symptoms was seen.
Conclusions: This study supports that simple treatment with oral contraceptives, oral gestagens, or the levonorgestrel-releasing intrauterine device represents a viable therapeutic approach to rectosigmoid DIE, provided that proper selection of patients in need of surgery exists.
However, some patients have limited problems that may be controlled by medical treatment, so avoiding the potentially severe complications of major surgery. This approach requires detailed knowledge on quality of life and clinical symptoms over time. The aim of the study was to monitor these parameters in patients with rectosigmoid endometriosis treated with oral contraceptives, oral gestagens, and/or the levonorgestrel‐releasing intrauterine device. Moreover, nodule size measurements performed with transvaginal sonography were correlated to severity of symptoms.
Material and methods: Conservatively treated patients on oral contraceptives, oral gestagens, or the levonorgestrel-releasing intrauterine device underwent transvaginal sonography and answered a self‐administered questionnaire regarding clinical symptoms and quality of life (Short Form 36 and Endometriosis Health Profile 30) at baseline, and 6 and 12 months later.
Results: Eighty women completed the follow up. Scores of quality of life were comparable
to normative data for Danish women of similar age and did not change with
time. No association between change in size of the rectosigmoid nodule and change in symptoms was seen.
Conclusions: This study supports that simple treatment with oral contraceptives, oral gestagens, or the levonorgestrel-releasing intrauterine device represents a viable therapeutic approach to rectosigmoid DIE, provided that proper selection of patients in need of surgery exists.
| Original language | English |
|---|---|
| Journal | Acta Obstetricia et Gynecologica Scandinavica |
| Volume | 98 |
| Issue | 9 |
| Pages (from-to) | 1139-1147 |
| Number of pages | 9 |
| ISSN | 0001-6349 |
| DOIs | |
| Publication status | Published - Sept 2019 |
Keywords
- bowel endometriosis
- deep infiltrating endometriosis
- dysmenorrhea
- endometriosis
- medical therapy
- oral contraceptives
- pelvic pain
- progestins